ENOB News and Press, Enochian Biosciences Inc. From 02/23/23

Enochian BioSciences ( NASDAQ: ENOB ) said Thursday it got a notice from Nasdaq stating that the company remains in non-compliance with the exchange's listing rules for not filing its Form 10-Q for the period ended December 31, 2022. The notification has no immediate effect on the...

LOS ANGELES, Feb. 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On February 16, 2023, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended ...

LOS ANGELES, Nov. 30, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- On November 23, 2022, Enochian BioSciences Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-Q for the period ended Septe...

LOS ANGELES, Oct. 24, 2022 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB)—Enochian BioSciences (the Company) recently announced significant progress toward re-prioritizing its focus on curing some of the world’s deadliest diseases. Last week, the Company announced its oncology pl...

Enochian BioSciences ( NASDAQ: ENOB ) received a notice from The Nasdaq that it is no longer in compliance with its rule as the company had not yet filed its Form 10-K. The Company has 60 calendar days to either file the Form 10-K or to submit to Nasdaq a plan to regain co...

LOS ANGELES, Oct. 21, 2022 (GLOBE NEWSWIRE) -- On October 17, 2022, Enochian BioSciences, Inc. (the "Company") received a notice (the "Notice") from The Nasdaq Stock Market LLC ("Nasdaq") stating that because the Company has not yet filed its Form 10-K, the Company is no longer in complianc...

Enochian BioSciences ( NASDAQ: ENOB ) stock rose ~5% on Monday after the company said that it received a U.S. patent for its proprietary cancer treatment platform which could potentially be used to induce life-long remission. Preclinical animal and laboratory ...

LOS ANGELES, Oct. 17, 2022 (GLOBE NEWSWIRE) -- Today, Enochian BioSciences (the Company) announced that it was awarded a U.S. patent for its proprietary cancer treatment platform that could potentially be used to induce life-long remission from some of the world’s deadliest solid tum...

New York, New York--(Newsfile Corp. - August 15, 2022) - Levi & Korsinsky, LLP notifies investors in Enochian BioSciences, Inc. ("Enochian" or the "Company") (NASDAQ: ENOB) of a class action securities lawsuit. The lawsuit on behalf of Enochian investors has been commenced in the the Un...

Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Enochian To Contact Him Directly To Discuss Their Options New York, New York--(Newsfile Corp. - July 31, 2022) - Faruqi & Faruqi, LLP, a leading national securities law firm, i...